Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease

SR Bramhall¹, GWH Stamp², J Dunn³, NR Lemoine² and JP Neoptolemos⁴

¹Department of Surgery, City Hospital NHS Trust Birmingham; ²ICRF Oncology Unit, Department of Histopathology, Royal Postgraduate Medical School, Hammersmith Hospital, London; ³Clinical Trials Unit, University of Birmingham, Birmingham; ⁴Academic Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK.

Summary It is now recognised that epithelial–stromal interactions are important in a wide range of disease processes including neoplasia and inflammation. Metalloproteinases are central to matrix degradation and remodelling, which are key events in tumour invasion and metastasis and may also be involved in tissue changes occurring in chronic inflammation. Immunohistochemistry was performed on sections from 50 patients with pancreatic cancer (n = 27), ampullary cancer (n = 12), low bile duct cancer (n = 3), neuroendocrine tumours (n = 3) and chronic pancreatitis (n = 5), using antibodies raised against collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of metalloproteinase (TIMP1) and developed using the avidin–biotin complex method. Abundance of MMP2, MMP3 and TIMP1 was greater in pancreatic and ampullary cancer than any other pathologic and immunohistochemical activity in the malignant epithelial cells in pancreatic and ampullary cancer was greater than in the stromal tissues (in pancreatic cancer: MMP2 100% vs 37%, MMP3 93% vs 15%, TIMP1 93% vs 4%, P < 0.0001). There were strong correlations between the immunoreactivity of the two antibodies for MMP2 (R < 0.0001), between MMP2 and TIMP1 (P < 0.0001) and between MMP3 and TIMP1 (P < 0.0001). The immunoreactivity for TIMP1 in pancreatic and ampullary cancers with lymph node metastases was significantly less compared with those cases without lymph node metastases (P < 0.02) and there was an association between increased immunoreactivity for MMP2 and the degree of tumour differentiation (P < 0.01). The results implicate MMP2, MMP3 and TIMP1 in the invasive phenotype of pancreatic and ampullary cancer.

Keywords: pancreatic cancer; collagenase; stromelysin; tissue inhibitor of metalloproteinase

Ductal adenocarcinoma of the pancreas is the fifth most common cause of cancer death in the western world (Haddock and Carter, 1990). Fewer than 10% of pancreatic cancers are resectable at the time of presentation, and even after resection the 5 year survival rate is only 10–15%. Periampullary cancers (arising from the ampulla of Vater or lower bile duct) are much less common than pancreatic cancer; they are often resectable and are associated with 5 year survival rates of 30% or more (Russell, 1990). The better outcome from ampullary cancer may be related to earlier presentation as survival for both types of cancer is strongly correlated with tumour grade, local invasion and lymph node metastasis (Neoptolemos et al., 1988; Yamaguchi and Enjoji, 1989).

The ability of malignant epithelial cells to break down adjacent extracellular matrix (ECM) (Hart et al., 1989) is an essential step in the processes of invasion and metastasis (Liotta et al., 1980; Liotta and Stetler-Stevenson, 1991). Loss of basement membrane integrity in breast and colorectal cancers have been shown to be associated with an increased risk of metastasis and poor prognosis (Charpin et al., 1986; Forster et al., 1986). In pancreatic cancers discontinuous or absent basement membrane type IV collagen is seen more frequently than in benign disease (Lee et al., 1994), and pancreatic cancer is characterised by aggressive local behaviour, early metastasis and an intense desmoplastic stromal reaction (Mollenhauer et al., 1987; Nagakawa et al., 1989, 1992).

The matrix metalloproteinases (MMP) are a family of proteolytic enzymes that are capable of degrading different substrates within the ECM (Cottam and Rees, 1993) and play a major role in the process of invasion and metastasis (Liotta et al., 1991). The functional activity of the activated forms of these enzymes appear to be controlled by three specific tissue inhibitors of metalloproteinases (TIMP1, 2, 3) (Cottam and Rees, 1993; Uria et al., 1994). The cellular source of MMPs is often difficult to identify in complex tissues. MMP1 (type I collagenase) appears to be a product of fibroblasts (Biswas, 1982), some tumour cell lines, including the pancreatic cancer cell line SUT12 (Taniguchi et al., 1992) and colonic tumours (Gray et al., 1993). MMP9 (92 kDa type IV collagenase) is also a product of some cancer cell lines (Okada et al., 1990, 1992; Shimia et al., 1993), squamous cell carcinoma of the skin (Pyke et al., 1992) and prostate adenocarcinoma (Hamdy et al., 1994) but also localises to tumour-infiltrating mononuclear cells, especially macrophages (Naylor et al., 1994). MMP3 (stromelysin) cleaves collagen types III, IV, V and IX and degrades gelatin, fibronectin, laminin, elastin and proteoglycan link protein (Chin et al., 1985). MMP3 has been shown to be produced by squamous cell carcinomas (Ostrowski et al., 1988; Matsrian et al., 1991). MMP10 (stromelysin 2) may be expressed in tumours with an epidermoid component (Muller et al., 1988), whereas MMP11 (stromelysin 3) is expressed in the stromal cells of breast cancer (Basset et al., 1990) and in colorectal malignancy (Urbanski et al., 1993). MMP7 (Pump 1) is a smaller enzyme involved in uterine involution but also has a putative role in colonic cancer development (Yoshimoto et al., 1993) and is expressed by some colorectal line cells (Miyazaki et al., 1990).

MMP2 (72 kDa type IV collagenase) activity is highly correlated with the invasive/metastatic phenotype. It is known to cleave basement membrane type IV collagen as well as V, VII, X and degrades gelatin, fibronectin, elastin and laminin (Murphy et al., 1991a,b). MMP2 has been shown to be produced by fibroblasts (Overall et al., 1991), endothelial cells (DeClerck et al., 1989; Unemori et al., 1992) and human cancer cell lines (Brown et al., 1990; Zucker et al., 1990; Agarwal et al., 1994) but in human colorectal,
breast and skin carcinomas most of the mRNA is found to localise to stromal fibroblasts (Poulson et al., 1992, 1993). This may be explained by cell-surface uptake by a putative receptor and membrane activation by a novel membrane-associated metalloproteinase (Sato et al., 1994).

Since TIMP1 and TIMP2 bind stoichiometrically with the activated form of the MMPs in a 1:1 ratio, small changes in the level of these enzymes may lead to biologically significant changes in proteolytic activity. TIMP1 binds to the activated forms of MMP1, MMP3 and MMP9 (Welgus and Stricklin, 1983; Welgus et al., 1985; Wilhelm et al., 1989), whereas TIMP2 inhibits both pro-MMP2 and activated MMP2 (Stetler-Stevenson et al., 1990). Both TIMP1 and TIMP2 have been shown to be produced in cancer cell lines in vitro (Stetler-Stevenson et al., 1990; Ponton et al., 1991) and the epithelial component of human adenocarcinomas in vivo (Hewitt et al., 1991; Poulson et al., 1992, 1993).

Our understanding of the MMPs in malignancy is still fragmented and their role in human pancreatic and ampullary cancers specifically is almost unknown, although experimental data have been reported for pancreatic cancer cell lines, concerning MMP1 and MMP2 (Moll et al., 1990; Zucker et al., 1992). The intense stromal reaction associated with pancreatic cancer (Mollenhauer et al., 1987) and its aggressive local invasive characteristics (Nagakawa et al., 1992), suggest that MMPs may play a role in the invasive phenotype of pancreatic cancer. This study reports the localisation of the protein products for MMP2, MMP3 and TIMP1 in these different types of cancer using immunohistochemistry.

Materials and methods

Antibodies

Four monoclonal murine antibodies were used that are specific to the 72 kDa type IV collagenase (MMP2, antibodies GL22 and GL8), stromelysin 1 (MMP3, antibody Mac78) and the tissue inhibitor of the metalloproteinases (TIMP1, antibody Mac15). These antibodies were raised against recombinant enzymes and subsequently characterised by Western blotting. They were compared with all members of the MMP/TIMP family to confirm specificity and absorption controls with recombinant enzymes performed

| Table I | Histopathology, stage and prognostically important factors of the sections used |
|---|---|---|---|---|
| Number | Adenocarcinoma pancreas | Ampullary adenocarcinoma | Low bile duct adenocarcinoma | Neuroendocrine tumours |
| T1 | 1 | (4%) | 5 | (42%) | 1 |
| T2 | 26 | (96%) | 5 | (42%) | 1 |
| T3 | 0 | 2 | (17%) | 1 |
| N0 | 11 | (41%) | 4 | (33%) | 2 |
| N1 | 16 | (59%) | 8 | (67%) | 1 |
| Tumour differentiation | | | | |
| Well | 11 | (41%) | 2 | (17%) | 2 |
| Moderate | 10 | (37%) | 3 | (25%) | 0 |
| Poor | 6 | (22%) | 7 | (58%) | 1 |
| Tumour size (cm) | | | | |
| <2 | 3 | (11%) | 5 | (42%) | 1 |
| 2-5 | 22 | (82%) | 4 | (33%) | 1 |
| >5 | 2 | (7%) | 1 | (8%) | 0 |

4Pancreas cancers were better differentiated than ampullary cancers (P<0.004). bMore pancreas cancers over 2 cm than ampullary cancers (P<0.009).

| Table II | Epithelial cell staining with the different antibodies |
|---|---|---|---|---|---|
| Antibody | Epithelial cell staining | Adenocarcinoma pancreas | Ampullary adenocarcinoma | Low bile duct adenocarcinoma | Neuroendocrine tumours | Chronic pancreatitis |
| GL22 72kDa Type IV collagenase (MMP2) | Negative | 0 | 0 | 0 | 2 | 0 |
| Weak | 4 | (15%) | 4 | (33%) | 2 | 1 |
| Moderate | 18 | (67%) | 5 | (42%) | 1 |
| Strong | 5 | (18%) | 3 | (25%) | 0 |

| GL8 72kDa Type IV collagenase (MMP2) | Negative | 0 | 0 | 0 | 2 | 0 |
| Weak | 12 | (44%) | 1 | (8%) | 0 | 1 |
| Moderate | 14 | (52%) | 10 | (83%) | 3 | 0 |
| Strong | 1 | (4%) | 1 | (8%) | 0 | 0 |

| Mac 78 Stromelysin 1 (MMP3) | Negative | 2 | (7%) | 1 | (8%) | 1 |
| Weak | 11 | (41%) | 5 | (42%) | 1 |
| Moderate | 8 | (30%) | 3 | (25%) | 1 |
| Strong | 5 | (18%) | 3 | (25%) | 1 |

| Mac 15 Tissue inhibitor of metalloproteinase (TIMP1) | Negative | 2 | (7%) | 0 | 0 | 1 |
| Weak | 21 | (78%) | 8 | (67%) | 2 | 2 |
| Moderate | 4 | (15%) | 4 | (33%) | 1 |
| Strong | 0 | 0 | 0 | 0 | 0 |
previously in our laboratories showed extinction of immunoreactivity (Afzal et al., 1995). The antibodies were provided by the research and development section of Celltech UK and are not commercially available.

**Tissue sections**

All sections were part of the archival tissue collection of the Department of Histopathology, Royal Postgraduate Medical School, Hammersmith Hospital. All tissues had been fixed in 10% formalin and mounted in paraffin blocks from which 4 μm tissue sections were taken on to poly-L-lysine coated slides.

The murine avidin–biotin complex method was used for antigen detection with antibody dilutions of 1:100 for GL8 (stock solution 1.57 mg ml⁻¹ IgG), 1:40 for GL22 (stock solution 2.77 mg ml⁻¹ IgG), 1:40 for Mac78 (stock solution 2.88 mg ml⁻¹ IgG) and 1:25 for Mac15 (stock solution 1.75 mg ml⁻¹ IgG). Sections were dewaxed and rehydrated through ethanol, endogenous peroxidase was blocked with hydrogen peroxide and non-specific protein binding was reduced using goat serum. The primary antibody was applied at the correct dilution in a volume of 50–100 μl and left overnight at 4°C. The primary antibody was removed and the sections washed in phosphate-buffered saline (PBS), biotinylated anti-murine goat antibody at a dilution of 1:500 was applied to each section and left for 1 h (Dako, High Wycombe, UK). The sections were washed in PBS and streptavidin-labelled peroxidase at a dilution of 1:500 was applied to the sections and left for 1 h (Dako). The sections were then washed for a third time in PBS and developed in 500 ml of 0.01% PBS, 0.025%, 3,3′-diamobenzidine tetrahydrochloride (Sigma, Poole, UK) and 500 ml of 30% hydrogen peroxide. The sections were washed again in PBS, counterstained using haematoxylin, dehydrated through alcohol and mounted in Perix (Cellpath, UK).

Specificity of immunostaining was established using a negative control for each section, missing out the primary antibody and using 100 μl of the diluent alone. Also included in each batch of sections was a known positive control previously validated within the laboratory by parallel in situ hybridisation and/or enzymology.

Sections were taken from 50 individual patients: 27 with ductal adenocarcinoma of the pancreas, 12 with ampullary cancer, three with lower bile duct cancer, three with neuroendocrine pancreatic tumours and five with chronic pancreatitis (Table I). All sections were stained with each antibody and scored independently by two individuals (GWHS, SRB) for intensity of staining of epithelial, stromal and normal tissue. Data were collected using the following scoring system: negative, 0; weak, 1/2; moderate, 3/4; strong, 5/6. The results were compared with TNM grading, tumour grade and tumour size.

**Statistical analysis**

Statistical analysis was performed using the Pearson chi-squared test, the chi-squared test for trend and for other data using the Fisher's exact test where applicable (BMDP Statistical Software package and InStat by Graphpad).

**Results**

The tumour and lymph node stage and tumour differentiation and size are shown in Table I. The intensity of staining in each tissue type with each antibody for epithelial, stromal and adjacent normal cells are shown in Tables II and III.

Immunoreactivities for MMP2, MMP3 and TIMP1 were greatest in adenocarcinomas of pancreas and ampulla compared with those in the other pathologies. None of the neuroendocrine tumours stained more than weakly with any

### Table III

| Antibody                        | Intensity of staining | Adenocarcinoma | Adenocarcinoma | Adenocarcinoma | Adenocarcinoma |
|---------------------------------|----------------------|----------------|----------------|----------------|----------------|
| GL22 72kDa Type IV collagenase  | Negative             | 17 (63%)       | 10 (83%)       | 23 (85%)       | 12 (100%)      |
| (MMP2)                          | Weak                 | 7 (26%)        | 2 (17%)        | 3 (11%)        | 0              |
|                                 | Moderate             | 3 (11%)        | 0              | 4 (14%)        | 0              |
|                                 | Strong               | 0              | 0              | 0              | 0              |
| GL8 72kDa Type IV collagenase   | Negative             | 16 (59%)       | 0              | 27 (100%)      | 12 (100%)      |
| (MMP2)                          | Weak                 | 9 (33%)        | 7 (58%)        | 0              | 0              |
|                                 | Moderate             | 2 (7%)         | 5 (42%)        | 0              | 0              |
|                                 | Strong               | 0              | 0              | 0              | 0              |
| Mac 78 Stromelysin1 (MMP3)      | Negative             | 22 (81%)       | 8 (67%)        | 25 (93%)       | 10 (83%)       |
|                                 | Weak                 | 3 (11%)        | 2 (17%)        | 1 (4%)         | 1 (8%)         |
|                                 | Moderate             | 1 (4%)         | 2 (17%)        | 0              | 1 (8%)         |
|                                 | Strong               | 0              | 0              | 0              | 0              |
| Mac 15 Tissue inhibitor or metalloproteinase (TIMP1) | Negative             | 26 (96%)       | 10 (83%)       | 25 (93%)       | 8 (67%)        |
|                                 | Weak                 | 1 (4%)         | 2 (17%)        | 2 (7%)         | 3 (25%)        |
|                                 | Moderate             | 0              | 0              | 0              | 1 (8%)         |
|                                 | Strong               | 0              | 0              | 0              | 0              |

### Table IV

| Lymph node status of patient | Intensity of epithelial cell staining with TIMP1 |
|------------------------------|-----------------------------------------------|
|                              | Weak              | Moderate            | Strong            |
| Pancreas cancer               |                  |                    |                   |
| Positive (n = 16)             | 14 (88%)          | 1 (6%)              | 0                 |
| Negative (n = 11)             | 7 (64%)           | 3 (27%)             | 0                 |
| Ampullary cancer              |                  |                    |                   |
| Positive (n = 8)              | 7 (88%)           | 1 (12%)             | 0                 |
| Negative (n = 4)              | 1 (25%)           | 3 (75%)             | 0                 |
of the antibodies, except MMP3, for which one tumour stained moderately. The pattern of staining in low bile duct tumours was similar to that in adenocarcinomas of the pancreas and ampulla.

All of the chronic pancreatitis sections showed immuno reactivity in acinar and ductal epithelial components with each antibody, which for MMP2 and MMP3 was at least moderately strong in three out of five, whereas for TIMP1 the epithelial staining was significant in only one out of five.

The immunoreactivity in the malignant epithelium was high with all of the antibodies in both adenocarcinomas of pancreas and ampulla (GL22 100% of pancreatic cases vs 100% of ampullary cases, GL8 100% vs 100%, Mac78 93% vs 92% and Mac15 93% vs 100%). In the malignant stromal tissue the immunoreactivity was much less (GL22 37% of pancreatic cases vs 17% of ampullary cases, GL8 40% vs 100%, Mac78 15% vs 34%, Mac15 4% vs 17%) and in normal tissue away from the malignant areas the immunoreactivity was even lower (GL22 15% of pancreatic cases vs 0% of ampullary cases, GL8 0% vs 0%, Mac78 4% vs 16%, Mac15 4% vs 33%) (Tables II and III).

With each antibody the epithelial cell staining was significantly stronger than either stromal or normal cell staining in both adenocarcinomas of the pancreas (P<0.0001) and ampulla (P<0.003) and with each antibody there was a significant trend for epithelial cells to have moderate to strong staining, stromal cells to have moderate to weak staining and normal tissue to be negative (P<0.0001).

There was strong correlation between the immunoreactivity of the two MMP2 antibodies (P<0.0001) and between MMP2 (GL22 or GL8) and MMP3 (P<0.0001). There was also correlation of expression between MMP2 (GL22 or GL8) and TIMP1 (P<0.0001) and between MMP3 and TIMP1 (P<0.0001), but this was only significant when the data were considered as two groups, negative compared with any level of immunoreactivity. The generally low levels of immunoreactivity of TIMP1 in the cancers and the small proportion of cases showing significant immunoreactivity justify this consideration.

Immunoreactivity for TIMP1 was absent or weak in 15 out of 16 cases of pancreatic cancer and four out of eight cases of ampullary cancer with lymph node metastases compared with eight out of 11 and one out of four cases respectively without lymph node metastases (P<0.02) (Table IV). There was increased immunoreactivity for MMP2 (GL8) with increasing tumour grade (P<0.01) (Table V).

There was no correlation or trend between lymph node stage or tumour differentiation and any of the other antibodies, nor between tumour stage and tumour size and any of the antibodies.

Table V Epithelial cell staining with the antibody to MMP2 (GL8) according to tumour differentiation

| Tumour cell differentiation | Intensity of epithelial cell staining with MMP2 | Negative | Weak | Moderate | Strong |
|----------------------------|-----------------------------------------------|---------|------|---------|-------|
| Pancreas cancer            |                                              |         |      |         |       |
| Well (n = 11)              | 0                                             |         | 6*  | 5* (55%) | 4* (45%) |
| Moderate (n = 10)         | 0                                             | 4       | 5   | 0       | 6* (100%) |
| Poor (n = 6)              | 0                                             | 0*      | 0   | 1 (14%) | 6* (86%) |
| Ampullary cancer          |                                              |         |      |         |       |
| Well (n = 2)              | 0                                             | 0       | 2   | 100%    | 0     |
| Moderate (n = 3)          | 0                                             | 0       | 2   | 67%     | 1 (33%) |
| Poor (n = 7)              | 0                                             | 1 (14%) | 6   | 86%     | 0     |

*P<0.01.

Figure 1 A poorly differentiated ampullary adenocarcinoma invading around unstained benign tubular glands (with polarised nuclei). The tubules and single cells of the carcinoma show moderately intense staining by MMP3 (Mac 78) (ABC-immunoperoxidase, original magnification x 250).

Figure 2 A poorly differentiated ductal adenocarcinoma of the pancreas showing moderate to strong heterogeneous cytoplasmic staining of the neoplastic cells for MMP3 (Mac 78). Weak staining of desmoplastic fibroblasts is also noted (ABC-immunoperoxidase, original magnification x 250).
Discussion

This study has shown the reactivity of the two antibodies recognizing MMP2 significantly correlated, reflecting their specificity. The immunoreactivity of MMP2 and MMP3 also correlated and this was perhaps surprising, as these two enzymes have different substrate specificities (Cottam and Rees, 1993) and appear to be important in different diseases. MMP3 plays a role in the activation of other members of the MMP family (Murphy et al., 1987; Ito and Nagase, 1988) although not in the case of MMP2 where MT-MMP is a likely candidate (Sato et al., 1994).

The antibodies to MMP2 (GL8 and GL22) both recognize pro-MMP2 and active MMP2 in solution phase, but in fixed tissues show a different reactivity pattern. GL22 demonstrates membrane and/or cytoplasmic staining which is polarised to the apex in differentiated cells, and rarely staining stromal cells while GL8 shows a cytoplasmic reactivity pattern in epithelial and stromal cells similar to other MMP2 antibodies that we have previously described (Poulsom et al., 1992).

MMP2 has been shown to be produced by the RWP-1 human pancreatic cancer cell line (Zucker et al., 1990). Plasma membrane fractions of the cell line were prepared by differential centrifugation and the membrane fraction extracted with N-butanol. Gelatin zymography showed proteinase bands of 92, 70 and 62 kDa and immunoblotting resulted in recognition of the 70 kDa protein but not the 92 kDa (Zucker et al., 1990). It has been suggested that it is the membrane localisation of the MMP2 in the pancreatic cancer cells that is critical rather than the species of type IV collagenase (Zucker et al., 1992). Certain human cancers have been shown to express MMP2, including adenocarcinoma of the colon, in which 10 out of 12 expressed the transcript for MMP2 but in desmoplastic fibroblasts rather than neoplastic cells. The same phenomenon was found in breast, skin and ovarian carcinomas (Poulsom et al., 1992, 1993; Naylor et al., 1994). The role of MMP3 in human adenocarcinoma is not well documented, although it appears to be important in the progression of squamous cell carcinomas (Ostrowski et al., 1988).

While immunoreactivities of both MMP2 and MMP3
(Figures 1 and 2) localised to the cytoplasm of the malignant epithelial cells in this series of pancreatic diseases, in many sections MMP2 (Figure 3) had large amounts of cellular membrane reactivity with the GL22 antibody especially at the invasion front. MMP2 appears to be produced in the stromal cells but activated and therefore localised by immunohistochemistry to the epithelial cells (Poulsom et al., 1992). The recent finding by Sato et al. (1994) of a new member of the matrix metalloproteinases which is membrane-bound (MT-MMP) and activates pro-MMP2 may help to explain these findings. There is no evidence that MMP3 is produced by stromal cells in the same way that MMP2 is, and this is confirmed by our findings of mainly cytoplasmic reactivity with this antibody. Although the specific inhibitor for MMP2 is TIMP2 (Stetler-Stevenson et al., 1990), TIMP1 will also bind MMP2 and elevated expression of TIMP1 transcripts was found in all five colorectal cancers examined in a recent series (Stetler-Stevenson et al., 1990). TIMP1 may be localised at the sites where MMP2 is active and this is supported by finding correlation of immunoreactivity for MMP2 and TIMP1 (Figures 3 and 4). The immunoreactivity of MMP3 and TIMP1 also correlated, in keeping with previous studies (Wilhelm et al., 1989).

It has been shown previously in human pancreatic cancer cells that expression of MMP1 correlated with spontaneous metastatic ability (Taniguchi et al., 1992). An increase in type I collagenolytic activity was noted in a subclone of the human pancreatic cancer cell line SUIT2 that demonstrated an increased metastasising ability in nude mice (Taniguchi et al., 1992). Reduced expression of TIMP is known to be associated with tumour cell line progression (Khoikka et al., 1991) but evidence for this in human tumours has been lacking. A putative reduction in TIMP expression in patients with lymph node metastasis from other cancer types has not been previously described. During the progression of tumours the check on proteolytic activity afforded by the specific enzyme inhibitors may be reduced, which allows a relatively greater proteolytic activity from MMP2 or other metalloproteinases (Liotta and Stetler-Stevenson, 1991). The inverse relationship between tumour differentiation and expression of MMP2 provides further evidence of a central role for this enzyme in pancreatic and ampullary tumour progression.

These data strongly implicate MMP2, MMP3 and TIMP1 in pancreatic and ampullary carcinoma progression. MMP2 immunoreactivity was directly related to tumour dedifferentiation (Figures 5 and 6) and invasive potential and reduced expression of its specific inhibitor (TIMP1) may be involved with increased metastatic ability. Although adenocarcinomas of the pancreas and ampulla of Vater show distinct differences in clinical outcome the present study supports the notion that these differences may be related to the stage of clinical presentation or biological characteristics other than the expression of MMP2, MMP3 and TIMP1.

References

AFZAL S, LALANI E-N, FOULKES W, CARDILLO M, BAKER T, PIGNATELLI M, DOCHERTY AJ AND STAMP GWH. (1995). Matrix metalloproteinase-2 expression in ovarian carcinomas and cell lines. Lab. Invest. (in press).

AGARWAL C, HEMBREE JR, RORKE EA AND ECKERT RL. (1994). Transforming growth factor beta 1 regulation of metalloproteinase production in cultured human cervical epithelial cells. Cancer Res., 54, 943–949.

BASSET P, BELLOCQ JP, WOLF C, STOLL I, HUTIN P, LIMACHE JM, PODHAIER OL, CHENARD MP, RIO MC AND CHAMBON P. (1990). A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature, 348, 699–704.

BISWAS C. (1982). Tumor cell stimulation of collagenase production by fibroblasts. Biochem. Biophys. Res. Commun., 109, 1026–1034.

BROWN PD, LEVY AT, MARGULIES IM, LIOTTA LA AND STETLER-STEVENSON WG. (1990). Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res., 50, 6184–6191.

CHARPIN C, LISITZKY JC, JACQUEMIER J, LAVAUT MN, KOPP F, POURREAU-SCHNEIDER N, MARTIN PM AND TOGA M. (1986). Immunohistochemical detection of laminin in 98 human breast carcinomas: A light and electron microscopic study. Hum. Pathol., 17, 355–365.

CHIN JR, MURPHY G AND WERR Z. (1985). Stromelysin, a connective tissue-degrading metalloendoproteinase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. J. Biol. Chem., 260, 12367–12376.

COTTAM DW AND REES RC. (1993). Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis (review). Int. J. Oncol., 2, 861–872.
OVERALL CM, WRANA JL AND SODEK J. (1991). Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J. Biol. Chem., 266, 14064–14071.

PONTON A, COULOMBE B AND SKUP D. (1991). Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res., 51, 2138–2143.

POULSON R, PIGNATELLI M, STETLER-STEVENSON WG, LIOTTA LA, WRIGHT PA, JEFFREY RE, LONGCROFT JM, ROGERS L AND STAMP GWH. (1992). Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol., 141, 389–396.

POULSON R, HANBY AM, PIGNATELLI M, JEFFERY RE, LONGCROFT JM, ROGERS L AND STAMP GWH. (1993). Expression of gelatine A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J. Clin. Pathol., 46, 429–436.

PYKE C, RALFKIAER E, TUHTALA P, HURSKAINE T, DANO K AND TRYGGVASON K. (1992). Localisation of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human cancers by in situ hybridisation. Cancer Res., 52, 1336–1341.

RUSSELL RC. (1990). Surgical resection for cancer of the pancreas. Bailliére’s Clin. Gastroenterol., 4, 889–916.

SATOH T, TAKINO T, OKADA H, SHIGAWA A, YAMAMOTO E AND SEIKI M. (1994). A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature, 370, 61–65.

SHIMA I, SASAGURI Y, KUSUKAWA J, NAKANO R, YAMANA H, FUJITA H AND KAKEGUCHI M. (1993). Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Br. J. Cancer, 67, 721–727.

STEHLER-STEVENSON WG, BROWN PD, ONISTO M, LEY AT AND LIOTTA LA. (1990). Tissue type and urokinase-type plasminogen activators (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J. Biol. Chem., 265, 13933–13938.

TANIGUCHI S, IWAMURA T AND KATSUKI T. (1992). Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cell line (SUIT-2) and sublines. Clin. Exp. Metastasis, 10, 259–266.

UNEMORI EN, FERRARA N, BAUER EA AND AMENTO EP. (1992). Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell Physiol., 153, 557–562.

URBANSKI ED, EDWARDS DR, HERSHFIELD N, HUCHCROFT SA, SHAFFER E, SUTHERLAND L AND KOSKASOKWA AE. (1993). Expression pattern of matrix metalloproteinases and tissue inhibitor changes with the progression of human sporadic colorectal neoplasia. Diagn. Mol. Pathol., 2, 81–89.

URA JI, FERRANDO AA, VELASCO G, FREIE JM AND LOPEZ OTIN C. (1994). Structural and expression in breast tumours of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res., 54, 2091–2094.

WELGUS HG AND STRICKLIN GP. (1983). Human skin fibroblast collagenase inhibitor. J. Biol. Chem., 258, 12259–12264.

WELGUS HG, JEFFREY JJ, EISEN AZ, ROSWIT WT AND STRICKLIN GP. (1985). Human skin fibroblast collagenase: interaction with substrate and inhibitor. Collagen Rel. Res., 5, 167–179.

WILHELM SM, COLLIER IE, MARMER BL, EISEN AZ, GRANT GA AND GOLDBERG GI. (1989). SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem., 264, 17123–17127.

YAMAGUCHI K AND ENJOJI M. (1989). Carcinoma of the pancreas: a clinicopathological study of 96 cases with immunohistochemical observations. J. Clin. Oncol., 19, 14–22.

YOSHIMOTO M, ITOH F, JUNG WY, HINODA Y, IMAI K AND YACHI A. (1993). Expression of MMP-7(PUMP-1) mRNA in human colorectal cancers. Int. J. Cancer, 54, 614–618.

ZUCKER S, MOLL UM, LYSIK RM, DIMASSIMO EI, STETLER-STEVENSON WG, LIOTTA LA AND SCHWEDES JW. (1990). Expression of type IV collagenase by human skin fibroblasts and plasma membranes of human cancer cells. Int. J. Cancer, 45, 1137–1142.

ZUCKER S, MOLL UM, LYSIK RM, DIMASSIMO EI, SCHWEDES JW AND LIOTTA LA. (1992). Extraction of type IV collagenase/ gelatinase from placenta membranes of human pancreatic cancer cell lines. Matrix Biol., 11, 47–54.